A Phase 2 interventional study of CP-675,206 in Refractory Melanoma, sponsored by AstraZeneca. Completed at 65 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-07.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tremelimumab in Melanoma — none open to participants now, none under way, none of them phase 3. tremelimumab · Melanoma.
Among the 12 studies testing tremelimumab in Melanoma, this one is the 2nd largest by enrollment, is the only one that started in 2005, is one of 5 in phase 2, and was the 2nd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 12 studies testing tremelimumab in Melanoma is open now. The open studies under Melanoma, anywhere →
tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tremelimumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 1
First in 2003; this study’s year is marked. 1 started in 2005.
This study's enrollment of 251 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 51 across the 12 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 6 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Melanoma by AstraZeneca: 2 open now, 3 under way, none of them phase 3. Of 17 finished, 2 (12%) have results posted.
Among the 20 studies in Melanoma by AstraZeneca, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2005, is one of 7 in phase 2, and was the 4th registered.
AstraZeneca’s Melanoma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing tremelimumab in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 20 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CP-675,206
15 mg/kg Q12W dosing regimen
To assess the anti-tumor efficacy, as determined by objective response rate, of intravenous CP-675,206 administered at a dose of 15 mg/kg every 90 days to patients with relapsed or refractory advanced melanoma
Time frame: Tumor response is assessed every 2-3 months until disease progression
Safety
Time frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug
Pharmaco Kinetic
Time frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug
Survival
Time frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug
Health-related QoL
Time frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug
The record gives a start of Dec 2005, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tremelimumab